Actavis UK Ltd & Ors v Eli Lilly & Company [2015] EWCA Civ 666 (30 June 2015)
Lilly is the overall winner and entitled to its costs, subject to deductions for the Rome II/DNI factual issues and direct infringement issues, with an issue-based assessment required for trial costs. No order as to costs of the appeal. The interim payment is reduced to £350,000. No recital of contractual undertaking is included. Permission to appeal is refused as no arguable point of law arises.
- Citation
- [2015] EWCA Civ 666
- Parties
- Claimants/respondents: Actavis UK Limited and others; Defendant/appellant: Eli Lilly & Company
- Jurisdiction
- England and Wales
- Judgment Date
- 30 June 2015
- Procedural Posture
- Civil Appeal / Post Judgment Consequential Matters
- Outcome
- Costs apportioned; interim payment reduced; no recital; permission to appeal refused.
- Legal Topics
- Patents, Costs, Direct Infringement, Indirect Infringement, Rome II Regulation, Declaratory Relief
Case Brief
Summary, issues, holding and outcome
More case intelligence is available
Unlock the full research layer for this judgment.
Parties
Actavis UK Limited and others
Claimants/respondents
Eli Lilly & Company
Defendant/appellant
Procedural Posture
Civil Appeal / Post Judgment Consequential Matters
Legal Issues
- 1 Entitlement to costs following mixed success at trial and appeal
- 2 Appropriate interim payment on account of costs
- 3 Whether to include recital of contractual undertaking in order
Ratio Decidendi
Lilly is the overall winner and entitled to its costs, subject to deductions for the Rome II/DNI factual issues and direct infringement issues, with an issue-based assessment required for trial costs. No order as to costs of the appeal. The interim payment is reduced to £350,000. No recital of contractual undertaking is included. Permission to appeal is refused as no arguable point of law arises.
Court Disposition
Costs apportioned; interim payment reduced; no recital; permission to appeal refused.
Orders
- Issue-based assessment of Rome II/DNI factual costs at trial; Lilly to recover 25% of its assessed costs after deduction of Rome II/DNI factual costs; Actavis to recover its costs of Rome II/DNI factual issues; balance payable to party entitled after assessment.
- No order as to costs of the appeal.
Full Case Text
Judgment text and source record
Sign in to read
Sign in to read the full judgment text
Sign in to read the full judgment text. Downloads and additional research tools may depend on your plan.
Sign in to read the full judgment